A first-in-human, phase I, dose-escalation study to evaluate pharmacokinetics, safety, and tolerability of KD6001, a novel anti-CTLA-4 monoclonal antibody (mAb) in patients with advanced solid tumors
Latest Information Update: 09 Jul 2024
At a glance
- Drugs KD-6001 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 09 Jul 2024 New trial record
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology